Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission CAMBRIDGE, Mass., Dec. 19...
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative...
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. ZURZUVAE, the...
Biogen Appoints Monish Patolawala to its Board of Directors Accomplished executive brings deep expertise leading global financial...
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in...
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting Late-breaking Phase 1b data assesses the...
Biogen Completes Acquisition of Reata Pharmaceuticals Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of...
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan TOKYO and CAMBRIDGE, Mass., Sept. 25...
Biogen Appoints Jane Grogan as Head of Research CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced...
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete...
Biogen to Acquire Reata Pharmaceuticals SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich’s...
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International...
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease The first and only approved treatment...
Biogen Announces Changes to Its Board of Directors Biogen Will Adjourn Its Annual Meeting of Stockholders Until June 26, 2023, to Give All...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.